Disc Medicine is a biopharmaceutical company dedicated to transforming the lives of patients with hematologic disorders. Disc Medicine is building a unique portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology. DISC-0974 is a first-in-class monoclonal antibody (mAB) against hemojuvelin (HJV) to suppress the production of hepcidin and enhance iron levels to treat anemia of inflammation. DISC-3405 is a mAb that inhibits TMPRSS6 (Transmembrane Serine Protease 6, also known as Matriptase-2) to induce endogenous expression of hepcidin. By increasing hepcidin levels to reduce iron levels, DISC-3405 has the potential to address a wide range of hematologic diseases.